Lupus Overview - Concepedia

Principles

Definition

Lupus is a significant research domain focused on understanding a chronic, systemic autoimmune disease characterized by the dysregulation of the immune system, leading to inflammation and damage across multiple organ systems. Academic inquiry in this field investigates the complex genetic and environmental factors contributing to its etiology, the molecular and cellular mechanisms of autoimmunity, the diverse clinical manifestations, and the development of diagnostic and therapeutic strategies.

Ontological type

Immunopathogenesis

Clinical Manifestations

Therapeutic Strategies

Key developments

Key Figures

Serology and Phenotyping era

Eng M. Tan[1] was a prominent lupus researcher associated with Rockefeller University[3] and the University of California, San Francisco[4] during the Serology and Phenotyping era. His key contributions included work on DNA antibodies and soluble nuclear antigens in SLE, exemplified by Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus[8] and Characteristics of a Soluble Nuclear Antigen Precipitating with Sera of Patients with Systemic Lupus Erythematosus[9], and were foundational for the 1982 revised criteria for the classification of systemic lupus erythematosus[7], which helped define autoantibody repertoires and established early serologic markers essential for classification in this era. Naomi F. Rothfield[2] was affiliated with Harvard University[5] and Johns Hopkins University[6] during this era. Her key contributions included work on The 1982 revised criteria for the classification of systemic lupus erythematosus[7] and Immunoglobulin Class and Pattern of Nuclear Fluorescence in Systemic Lupus Erythematosus[10], which helped standardize classification and serologic phenotyping—foundational for epidemiology, cohort phenotyping, and clinical decision frameworks in serology-driven lupus research.

Antigen-Driven Immune Dysregulation era

Dafna D. Gladman [1] is associated with the University of Toronto [3] and McMaster University [4] during this era. Her key contributions include co-developing the Systemic Lupus Erythematosus Disease Activity Index [6], a standardized measure of disease activity that enabled cross-study comparisons in the antigen-driven dysregulation era. Murray B. Urowitz [2] is associated with the University of Toronto [3] and the University of Waterloo [5] during this era. He co-authored the 2007 SLEDAI paper [6] and the 2002 infection study The nature and outcome of infection in systemic lupus erythematosus [7], contributions that highlighted how infections intersect with immune dysregulation to shape lupus management in this period.

Interferon-Driven Immunopathology era

Joan T. Merrill [1], affiliated with Harvard University [3] and Stanford University [4], shaped lupus research during the interferon-driven era. Her contributions include the 2012 American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis [7], the Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci [8], and the 2009 identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus [9], which collectively informed nephritis management, genetic susceptibility mapping, and innate immune signaling in this era. Mariana J. Kaplan [2], affiliated with University of Pennsylvania [5] and University of California, Los Angeles [6], contributed to understanding neutrophil biology in lupus during this era. Her work, including Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease [10], Netting Neutrophils Induce Endothelial Damage, Infiltrate Tissues, and Expose Immunostimulatory Molecules in Systemic Lupus Erythematosus [11], and Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus [12], advanced the concept of interferon-driven innate immunity as a therapeutic target in this era.